Artemis Institute for Clinical Research

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Obesity7 trials
• Alzheimer disease4 trials
• Migraine3 trials
• Obstructive sleep apnoea2 trials
• Osteoarthritis2 trials
• Type 2 diabetes2 trials
• Fatty liver disease (MASLD/MASH)1 trial

Phase

• Phase 314 trials
• Phase 22 trials

Status

• Recruiting9 trials
• Active, not recruiting4 trials
• Completed2 trials
• Terminated2 trials

Lead sponsor

• Eli Lilly and Company10 trials
• Amgen2 trials
• Cassava Sciences, Inc.2 trials
• TriGemX Bio, Inc.2 trials
• Rehaler1 trial

Running trials

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Eli Lilly and Company· Source

  Contact: Jack Vu (principal investigator)

• Recruiting

  A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07674654· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  NCT07684235· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07645924· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain

  NCT07641517· Phase 2· Eli Lilly and Company· Source

  Contact: Jack Vu (principal investigator)

• Recruiting

  A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

  NCT07602582· Phase 3· Eli Lilly and Company· Source

  Contact: Jack Vu (principal investigator)

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT07369011· Phase 3· Eli Lilly and Company· Source

  Contact: Jack Vu (principal investigator)

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

  NCT07232719· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Jack Vu (principal investigator)

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Amgen· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

  NCT05986292· Phase 2· Eli Lilly and Company· Source

  Contact: Jack Vu (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Migraine2 recruiting
• Osteoarthritis2 recruiting
• Alzheimer disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Obstructive sleep apnoea1 recruiting

Closed trials

• Terminated

  PArtial REbreathing for Migraine With Aura 1

  NCT05546385· Rehaler· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

  NCT05412004· Phase 3· Eli Lilly and Company· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Cassava Sciences, Inc.· Source